表紙
市場調査レポート

融合タンパク質、抗体および細胞におけるエンジニアドT細胞受容体:バイオ医薬品業界にとっての新たな機会

The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry

発行 La Merie Publishing 商品コード 288582
出版日 ページ情報 英文 84 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
融合タンパク質、抗体および細胞におけるエンジニアドT細胞受容体:バイオ医薬品業界にとっての新たな機会 The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry
出版日: 2013年10月25日 ページ情報: 英文 84 Pages
概要

治療用モノクローナル抗体は2012年に650億米ドルの売上を達成するなど治療モダリティとして大きく成長しています。2006年から2012年の平均年間成長率は18.9%となっています。

当レポートでは、融合タンパク質、抗体、細胞におけるエンジニアドT細胞受容体市場について調査し、各セグメントの参入企業の動向、製品概要、研究開発パイプラインなどをまとめ、概略下記の構成で取り上げております。

第1章 エグゼクティブサマリー

第2章 イントロダクション

第3章 T細胞受容体

第4章 TCR融合タンパク質

  • Altor Bioscience
    • 概要
    • 財務実績
    • 知的財産保護
    • 提携 その他
  • Immunocore
    • 企業の発展
    • 提携
    • 評価 他

第5章 TCR様(TCRL)抗体

  • Eureka Therapeutics & Memorial Sloan-Kettering Cancer Center
    • TCRL抗体の標的
    • TCRL抗体の生成
    • TCRL抗体前臨床特性 他
  • Applied Immune Technologies
    • 企業の背景
    • 財務実績
    • 癌標的
    • 技術 他

第6章 TCRトランスフェクトT細胞

  • Adaptimmune
    • 企業の背景
    • 製造概要 他
  • TCRトランスフェクトT細胞の学術研究

第7章 "人工"TCRT細胞:キメラ抗原受容体(CAR)T細胞

  • 癌のためのCAR修飾T細胞
  • 自己CAR修飾T細胞
  • 同種CAR修飾T細胞
  • CAR修飾多能性幹細胞

第8章 腫瘍浸潤リンパ球(TILs)

第9章 TCRに基づく製品および技術の機会分析

第10章 参考

第11章 企業の研究開発パイプライン

  • Adaptimmune
  • Altor Bioscience
  • Immunocore
  • Lion Biotechnologies

図表

目次
Product Code: LMFR0009

A comparative analysis and assessment of TCR technologies, pipelines and companies from an industry perspective

Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (continuous) annual growth rate from 2006 to 2012 of 18.9%. While antibody technologies are steadily evolving, the spectrum of druggable targets for monoclonal antibodies has remained limited to extracellular antigens, albeit including proteins, carbohydrates and glycolipids.

Access to druggable, IP-protected and validated new targets is a major bottleneck in the biopharmaceutical industry. Technologies which can deliver both new targets and the corresponding treatment modality, can expect significant financial acknowledgement.

The T-cell receptor (TCR) has recently emerged as a means to target peptide antigens derived from intracellular proteins, however, in a major histocompatibility complex (MHC)-restricted manner. The first companies have overcome significant technical hurdles in putting together a library of viable new TCR-targeted antigens and establish the corresponding standardized protein- and cell-based therapeutic frameworks.

This report entitled “The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry” published in Ocotber 2013 describes chances and pitfals in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products. The key success factors are highlighted, the technical challenges described and solutions presented.

Benefits from the report:

  • Identify players in the field, from industry and academia;
  • Find out which TCR technologies are valued by Big Pharma and Biotech;
  • Understand the value of intracellular antigens targeted by the TCR;
  • Recognize the challenges of TCR-based therapeutics and their solutions;
  • Learn which TCR-based therapeutics are attractive for partnering;
  • Find out which TCR therapeutic approaches are not yet tapped.

SAMPLE

10.1: Adaptimmune - 3/3

Table of Contents

0. List of Abbreviations

1. Executive Summary

2. Introduction

3. The T-Cell Receptor

4. TCR Fusion Proteins

  • 4.1. Altor Bioscience
    • 4.1.1. Overview
    • 4.1.2. Financing history
    • 4.1.3. IP protection
    • 4.1.4. Partnering
    • 4.1.5. STAR technology
    • 4.1.6. Binding affinity of scTCRs
    • 4.1.7. Manufacturing of STAR molecules
    • 4.1.8. Targets for scTCRs
    • 4.1.9. Generation of scTCRs
    • 4.1.10. Other applications of STAR molecules
    • 4.1.11. STAR pipeline
    • 4.1.12. ALT-801
      • 4.1.12.1. Preclinical characterization of ALT-801
      • 4.1.12.2. Clinical results of studies with ALT-801
      • 4.1.12.3. Ongoing clinical studies with ALT-801
      • 4.1.12.4. Safety of ALT-801 in clinical studies
      • 4.1.12.5. Clinical immunogenicity of ALT-801
      • 4.1.12.6. Clinical pharmacokinetics of ALT-801
    • 4.1.13. ALT-802
    • 4.1.14. Assessment
  • 4.2. Immunocore
    • 4.2.1. Corporate development of Immunocore
    • 4.2.2. Stability and solubility of TCRs
    • 4.2.3. Affinity of monoclonal TCRs (mTCR)
    • 4.2.4. Effector function for mTCR
    • 4.2.5. Target discovery for mTCRs
    • 4.2.6. Preclinical experience with mTCRs
    • 4.2.7. ImmTAC clinical lead program
    • 4.2.8. Partnering
    • 4.2.9. Assessment

5. TCR-Like (TCRL) Antibodies

  • 5.1. Eureka Therapeutics & Memorial Sloan-Kettering Cancer Center
    • 5.1.1. Target of TCRL antibody
    • 5.1.2. Generation of TCRL antibody
    • 5.1.3. Preclinical characterization of TCRL antibody
    • 5.1.4. Intellectual property
    • 5.1.5. Corporate background
    • 5.1.6. Assessment
  • 5.2. Applied Immune Technologies
    • 5.2.1. Corporate background
    • 5.2.2. Financial history
    • 5.2.3. Cancer target
    • 5.2.4. Technologies
    • 5.2.5. Viral targets
    • 5.2.6. Generation of TCRL antibodies
    • 5.2.7. Assessment

6. TCR-Transfected T-Cells

  • 6.1. Adaptimmune
    • 6.1.1. Corporate Background
    • 6.1.2. Overview of manufacturing
    • 6.1.3. The TCR engineering process
    • 6.1.4. TCR-transfected T-cells versus CAR-transfected T-clls
    • 6.1.5. Clinical R&D in cancer
    • 6.1.5. Clinical HIV study with TCR T-cells
    • 6.1.6. Assessment
  • 6.2. Academic Studies with TCR-Transfected T-Cells

7. “Artificial” TCR T-Cells: Chimeric Antigen Receptor (CAR) T-Cells

  • 7.1. CAR-modified T-cells for cancer
    • 7.1.1. Background
    • 7.1.2. Clinical experience with CAR-modified T-cells
    • 7.1.3. The three generations of CAR-Modified T-cells
    • 7.1.4. Assessment
  • 7.2. Autologous CAR-Modified T-Cells
    • 7.2.1. Novartis & The University of Pennsylvania
    • 7.2.2. Celgene & bluebird bio & Baylor College of Medicine
    • 7.2.3. Kite Pharma
  • 7.3. Allogeneic CAR-Modified T-Cells
    • 7.3.1. Cellectis
  • 7.4. CAR-Modified Induced Pluripotent Stem Cells

8. Tumor-Infiltrating Lymphocytes (TILs)

  • 8.1. Lion Biotechnologies

9. Opportunity Analysis for TCR-based Products and Technologies

10. References

11. Corporate R&D Pipelines

  • 11.1. Adaptimmune
  • 11.2. Altor Bioscience
  • 11.3. Immunocore
  • 11.4. Lion Biotechnologies

Tables in the Text

  • Table 1: Financing history of Altor Bioscience
  • Table 2: Financing history of Immunocore
  • Table 3: Affinity enhancement of TCRs by Immuncore technology
  • Table 4: Comparison of TCR T-Cells with CAR T-Cells
  • Table 5: Investigator sponsored clinical studies with TCR
Back to Top